Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO)

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/abstract?utm_campaign=infocusalerts-oncology&utm_medium=email&dgcid=hubspot_email_infocusalerts-oncology&_hsenc=p2ANqtz-8H9FrVKU2lKwP93KdFR2tb_4BiDOylwgICI4yF1ziupzAwjW4EgeO2MRihj3Fu3gHvRDRtZJvavFxxrbapS514TSP7RQ&_hsmi=333150588&utm_content=332418629&utm_source=hs_email